Back to News
Apr 9, 2026 4:00 PM

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

Anbio Biotechnology (NASDAQ:NNNN) reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024.

Net income surged to $6.4 million, up from $2.37 million, while earnings from continuing operations jumped to 15 cents per share from 6 cents.

Gross margin expanded to 87.2% from 71.9%, driven by a higher-margin product mix and an outsourcing-led model, boosting profitability. Return on equity improved to roughly 21.1%.

Pivot Away From COVID Diagnostics

Anbio, a medical technology and vitro diagnostics (IVD) company, has been actively diversifying away from COVID-19 diagnostics. In 2025, the company launched:

Dry chemiluminescence immunoassay (CLIA) – platform combining traditional CLIA with ease of ...